Sancy Leachman on Monitoring for Melanoma Recurrences
Sancy Leachman, MD, PhD, professor and chair, Department of Dermatology, director, Melanoma Research Program, Knight Cancer Institute, Oregon Health & Science University, discusses how a mobile app can help oncology professionals monitor patients for melanoma.
Sancy Leachman, MD, PhD, professor and chair, Department of Dermatology, director, Melanoma Research Program, Knight Cancer Institute, Oregon Health & Science University, discusses how a mobile app can help oncology professionals monitor patients for melanoma.Â
Patients who had one incidence of melanoma are approximately eight times more likely to develop the disease again, Leachman says, and these patients require close monitoring throughout their lifetimes.Â
Oregon Health & Science University created an app, Mole Mapper, which allows patients to measure and monitor their moles for melanoma. Leachman says patients can use the app and share the information with their oncologists to determine if further testing or treatment is needed.Â
Cemiplimab as Adjuvant Therapy Improves DFS in High-Risk Cutaneous Squamous Cell Carcinoma
January 20th 2025Adjuvant cemiplimab demonstrated a statistically significant improvement in DFS compared to placebo in post-surgical patients with high-risk CSCC, impacting post-operative care considerations.
